Iguana Healthcare Management LLC lowered its holdings in shares of Diplomat Pharmacy, Inc. (NYSE:DPLO) by 20.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 60,000 shares of the company’s stock after selling 15,000 shares during the quarter. Iguana Healthcare Management LLC owned 0.09% of Diplomat Pharmacy worth $1,243,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. PNC Financial Services Group Inc. grew its holdings in shares of Diplomat Pharmacy by 46.7% during the second quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock worth $130,000 after buying an additional 2,794 shares in the last quarter. Municipal Employees Retirement System of Michigan grew its holdings in shares of Diplomat Pharmacy by 4.9% during the second quarter. Municipal Employees Retirement System of Michigan now owns 10,250 shares of the company’s stock worth $152,000 after buying an additional 480 shares in the last quarter. Janney Montgomery Scott LLC grew its holdings in shares of Diplomat Pharmacy by 11.9% during the second quarter. Janney Montgomery Scott LLC now owns 11,193 shares of the company’s stock worth $166,000 after buying an additional 1,193 shares in the last quarter. Bank of Montreal Can grew its holdings in shares of Diplomat Pharmacy by 3.0% during the second quarter. Bank of Montreal Can now owns 11,600 shares of the company’s stock worth $172,000 after buying an additional 340 shares in the last quarter. Finally, Trexquant Investment LP bought a new position in shares of Diplomat Pharmacy during the second quarter worth about $180,000. 72.48% of the stock is currently owned by institutional investors.
In other Diplomat Pharmacy news, Director Jeffrey G. Park acquired 3,000 shares of the business’s stock in a transaction dated Monday, November 20th. The stock was bought at an average cost of $15.46 per share, with a total value of $46,380.00. Following the completion of the transaction, the director now directly owns 7,640 shares in the company, valued at approximately $118,114.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, President Joel Saban acquired 10,000 shares of the business’s stock in a transaction dated Monday, November 20th. The stock was acquired at an average cost of $15.24 per share, with a total value of $152,400.00. Following the completion of the transaction, the president now owns 12,000 shares of the company’s stock, valued at $182,880. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 15,000 shares of company stock valued at $228,780. Corporate insiders own 30.20% of the company’s stock.
Diplomat Pharmacy, Inc. (DPLO) opened at $20.26 on Thursday. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.34 and a quick ratio of 0.82. The firm has a market capitalization of $1,368.51, a P/E ratio of 25.81, a price-to-earnings-growth ratio of 3.58 and a beta of 0.61. Diplomat Pharmacy, Inc. has a one year low of $12.25 and a one year high of $21.99.
Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings results on Monday, November 6th. The company reported $0.25 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.10. The firm had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.16 billion. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. The business’s revenue was down 4.8% compared to the same quarter last year. During the same period last year, the company earned $0.21 earnings per share. equities research analysts predict that Diplomat Pharmacy, Inc. will post 0.85 EPS for the current year.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy, Inc. (NYSE:DPLO).
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.